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With growing calls to improve value in health care, the assessment of surgical 
outcomes has moved to the spotlight. Public awareness of medical errors has 
spurred initiatives like the ProPublica “Surgeon Scorecard” to measure and 
report complications (https://projects.propublica.org/surgeons/). High-tech and 
expensive innovations such as robot-assisted surgery must be measured against 
traditional approaches. Together, these factors and others have spurred calls to 
measure, assess and compare surgical techniques. The past months have seen 
publication of two high-profile randomized trials evaluating surgical techniques in 
urology. The first was early results from the first phase-3 randomized trial 
comparing open and robotic prostatectomy.[1] Second was the publication of 10-
year outcomes from the ProtecT trial, comparing surgery, radiation and active 
monitoring for prostate cancer.[2]   
 
Using trials to evaluate techniques is seemingly obvious. Since James Lind’s first 
trial of treatments for scurvy on eighteenth-century British sailors, prospective 
randomized trials have been the gold standard for assessing medical 
interventions. The concept is simple. Patients are assigned to one or more 
interventions and otherwise treated the same. Properly designed randomized 
trials can minimalize spurious causality, reduce bias and give as close a picture 
to “true” causal relationships as possible. The authors of such clinical trials 
should be commended given the years of work and substantial hurdles 
involved in designing and executing these trials. With that said, we believe 
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that there are some key issues which should be highlighted when clinical trials 
are used to evaluate surgical techniques and effectiveness. 
 
Among the most evident limitations of surgical trials are practical considerations.  
While use of placebos, allocation concealment and blinding is de rigueur in 
pharmaceutical trials, these are difficult to achieve in surgery. Some aspects of 
surgical technique, for example stapled versus sewn anastomosis, or small 
differences in equipment can be tested without patients or outcomes assessors 
being aware. But blinding patients to large differences in technique (e.g. open 
versus robotic approach) or surgical versus non-surgical approaches (e.g. 
surgery versus radiation or endoscopic approaches) is challenging.  
 
Additionally, there is a large question about confounding. For all but the smallest 
details of operative techniques, patients’ clinical team must know what surgery 
has been done.  This is vital for providing appropriate postoperative care, but 
also allows for potential differences in care, which could skew outcomes.  
 
The generalizability of surgical trials may be an issue if the surgeons in the study 
are not representative of those in non-academic practice. To use a recent 
example – both the Asymptomatic Carotid Trial 1 (ACT I) and Carotid 
Revascularization Endarterectomy versus Stenting Trial [3] published results 
comparing surgical versus endovascular treatment of asymptomatic carotid 
artery stenosis.[3] [4] Both used a credentialing process to guarantee that only 
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the best surgeons and interventionists performed the interventions.[5] But even 
when these steps are taken, if the procedures turn out to have greatly different 
learning curves or require different levels of skill, results achieved at high-volume 
academic centers may not be seen at non-academic or private centers.  
 
Another issue related to headline-grabbing clinical trials is that media-
based dissemination of information on novel surgical techniques leads to 
alteration in practice-based non-representative surgical practice, these 
changes may be unwarranted. There are examples of media 
misinterpretation of clinical studies 
(http://www.nytimes.com/2016/07/21/health/advanced-prostate-cancer-
false-alarm.html)  – headlines often fail to convey the clinical complexity 
and true content of many types of studies. 
 
Ultimately, trials comparing surgical techniques depend on surgeon expertise. 
The most that a clinical trial of surgery can show is whether surgeons A, B, C 
performing procedure X are better than surgeons D, E, F performing procedure 
Y. For example, in the above study by Yaxley, et al, men were randomized to 
either open surgery with surgeon A, or robotic surgery with surgeon B. The 
authors should be commended for planning and executing this innovative and 
challenging study. But does this really answer the question? Patients and the 
public need to know if robot-assisted prostatectomy is generally better, not 
whether surgeon A is better than surgeon B at their respective techniques. 
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Preoperative selection, operative technique, surgical equipment, and post-
operative care are components of complicated systems with multiple inputs and 
interlocking parts. Finding out how to optimize operative systems and techniques 
is vital – but may require analytic techniques that go beyond traditional 
randomized trials. 
 
When large companies try to optimize manufacturing systems or large global 
supply chains, they experiment, analyze and adapt. Real-time data gathering 
allows fine-tuning. It wouldn’t make sense to design a series of vast “trials” where 
products are “randomized” to different manufacturing systems altering only one 
variable at a time in complex supply and manufacturing systems, with results 
measured for months or years.  Analytic tools such as statistical process control 
and design of experiments allows these companies to determine and measure 
important variables in complex systems.[6] These techniques may prove vital in 
the study of complex systems like surgical care.  
 
Randomized controlled trials provide ironclad evidence on the superiority of drug 
A versus B or versus placebo. They can also provide key insight on some 
questions in surgery. However, at the same time, it is essential to understand 
how surgery is different. It is often said that surgery is more “an art than a 
science.” While this cliché does not excuse us from applying scientific rigor, it 
does highlight that surgery may require novel evaluative approaches compared 
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to prospective trials. We believe that novel; data-driven approaches that 
encompass the complexity of surgical care will provide key complementary 
insights for surgical evaluation and quality improvement in years to come. 
 
In fact, there are already examples of pioneering surgical improvement initiatives 
such as the Michigan Surgical Quality Collaborative in the United States, or the 
IDEAL collaborative in the United Kingdom (http://www.ideal-
collaboration.net/), which emphasize real-time, systems-based improvements 
and analysis within existing hospital systems. The paradigm of such initiatives 
is that innovation; evaluation and validation in complex and dynamic 
systems such as surgery can and should happen in parallel, and that while 
clinical trials provide extremely reliable information, complementary and 
more nimble approaches are vital as well. 
 
 
1. Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, 
Zajdlewicz L, et al. Robot-assisted laparoscopic prostatectomy versus open radical 
retropubic prostatectomy: early outcomes from a randomised controlled phase 3 
study. The Lancet. 
2. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-
Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate 
Cancer. The New England journal of medicine. 2016. 
3. Brott TG, Howard G, Roubin GS, Meschia JF, Mackey A, Brooks W, et al. Long-
Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. The 
New England journal of medicine. 2016;374(11):1021-31. 
4. Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, et 
al. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. 
The New England journal of medicine. 2016;374(11):1011-20. 
5. Spence JD, Naylor AR. Endarterectomy, Stenting, or Neither for 
Asymptomatic Carotid-Artery Stenosis. The New England journal of medicine. 
2016;374(11):1087-8. 
 7 
6. O'Brien T, Viney R, Doherty A, Thomas K. Why don't mercedes benz publish 
randomized trials? BJU international. 2010;105(3):293-5. 
 
